中国临床药理学杂志2018，Vol.34Issue(9)：1039-1041,1059,4.DOI:10.13699/j.cnki.1001-6821.2018.09.009
吉西他滨注射剂联合替吉奥胶囊治疗胰腺癌的临床研究
Clinical trial of gemcitabine injection in combination with tegafur, gimeracil and oteracil porassium capsules in the treatment of patients with pancreatic cancer
摘要
Abstract
Objective To observe the efficacy and safety of gemcitabine injection in combination with tegafur,gimeracil and oteracil porassium capsules in the treatment of pancreatic cancer.Methods A total of 60 patients with pancreatic cancer were randomly divided into control group (n =30) and treatment group (n =30).The control group was given intravenous infusion of gemcitabine injection (1000 mg · m-2,30 min) on the first,eighth and fifteenth day of treatment.On the basis of the control group,the treatment group was received oral administration of tegafur,gimeracil and oteracil porassium capsules (80 mg · m-2 · d-1) on the first and fifteenth day of treatment.Both groups were treated for 4 cycles.The clinical efficacy,natural killer T cells (NKT),interferon-γ (IFN-γ),T lymphocyte subsets (CD3+,CD+,CD8+) level,and adverse drug reactions were compared.Results After treatment,the total effective rates of the treatment group and control group were 86.67％ (26 cases/30 cases) and 63.33％ (19 cases/30 cases),respectively,with significant difference (P ＜0.05).After treatment,there were significant differences between the treatment group and the control group in NKT [(16.61 ±1.26) ％ vs (14.04±1.59) ％,IFN-γ [(7.27±0.47) μ,g· L-1vs (5.30±0.90) μ,g · L-1],CD3+ [(70.02 ±4.0)％ vs (65.94 ± 5.56)％];CD4+ [(41.64 ± 2.41)％ vs (38.87 ± 2.30)％];CD8+ were [(36.77 ±1.75)％ vs (38.23 ± 1.62)％];CD4+/ CD8+ were(1.27 ±0.11 vs 1.15 ±0.08) (P＜0.05).The adverse drug reactions of the two groups were mainly nausea,vomiting,diarrhea,and granulocytes,The incidence sof adverse reactions of the treatment group and the control group were 20.00％ (6 cases/30 cases) and 23.33％ (7 cases/30 cases),respectively,without significant difference(P ＞ 0.05).Conclusion Gemcitabine injection in combination with tegafur,gimeracil and oteracil porassium capsules showed efficacy higher than gemcitabine alone in the treatment of pancreatic cancer,with a similar safety profile.关键词
吉西他滨/替吉奥/胰腺癌/自然杀伤T细胞/T细胞亚群/γ干扰素Key words
gemcitabine/tegafur/pancreatic cancer/natural killer T cell/T cell subgroup/interferon-γ分类
医药卫生引用本文复制引用
徐安保,吉顺莉,倪润洲,肖明兵..吉西他滨注射剂联合替吉奥胶囊治疗胰腺癌的临床研究[J].中国临床药理学杂志,2018,34(9):1039-1041,1059,4.基金项目
国家自然科学基金资助项目(81101802) （81101802）
南通市社会事业科技创新与示范计划基金资助项目(HS2014072) （HS2014072）
